Editorial: is tofacitinib another rescue option for acute severe ulcerative colitis?

Sailish Honap; Polychronis Pavlidis; Peter M. Irving

doi:10.1111/apt.16482

Editorial: is tofacitinib another rescue option for acute severe ulcerative colitis?

Sailish Honap^*, Polychronis Pavlidis, Peter M. Irving

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › peer-review

2 Citations (Scopus)

Original language	English
Pages (from-to)	341-342
Number of pages	2
Journal	Alimentary Pharmacology and Therapeutics
Volume	54
Issue number	3
DOIs	https://doi.org/10.1111/apt.16482
Publication status	Published - Aug 2021

Access to Document

10.1111/apt.16482

Cite this

@article{030da048392b483db7e93ba48b2fa4d6,

title = "Editorial: is tofacitinib another rescue option for acute severe ulcerative colitis?",

author = "Sailish Honap and Polychronis Pavlidis and Irving, {Peter M.}",

note = "Funding Information: Declaration of personal interests: SH has served as a speaker for Pfizer, Janssen and Takeda. Polychronis Pavlidis has received research funding from Galapagos. PI has served as a speaker, and/or a consultant, and/or an advisory board member for Abbvie, Warner Chilcott, Ferring, Falk Pharma, Takeda, MSD, Johnson and Johnson, Shire, Pfizer, Vifor Pharma, Pharmacosmos, Topivert, Genentech, Hospira and Samsung Bioepis, and has received research funding from MSD, Takeda and Pfizer. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = aug,

doi = "10.1111/apt.16482",

language = "English",

volume = "54",

pages = "341--342",

journal = "Alimentary Pharmacology and Therapeutics",

issn = "0269-2813",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "3",

}

TY - JOUR

T1 - Editorial

T2 - is tofacitinib another rescue option for acute severe ulcerative colitis?

AU - Honap, Sailish

AU - Pavlidis, Polychronis

AU - Irving, Peter M.

N1 - Funding Information: Declaration of personal interests: SH has served as a speaker for Pfizer, Janssen and Takeda. Polychronis Pavlidis has received research funding from Galapagos. PI has served as a speaker, and/or a consultant, and/or an advisory board member for Abbvie, Warner Chilcott, Ferring, Falk Pharma, Takeda, MSD, Johnson and Johnson, Shire, Pfizer, Vifor Pharma, Pharmacosmos, Topivert, Genentech, Hospira and Samsung Bioepis, and has received research funding from MSD, Takeda and Pfizer. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/8

Y1 - 2021/8

UR - http://www.scopus.com/inward/record.url?scp=85109379962&partnerID=8YFLogxK

U2 - 10.1111/apt.16482

DO - 10.1111/apt.16482

M3 - Editorial

AN - SCOPUS:85109379962

SN - 0269-2813

VL - 54

SP - 341

EP - 342

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

IS - 3

ER -

Editorial: is tofacitinib another rescue option for acute severe ulcerative colitis?

Access to Document

Other files and links

Cite this